Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage.
Ontology highlight
ABSTRACT: We conducted a post hoc analysis to assess the potential impact of GAP (gender, age, physiology) stage on the treatment effect of nintedanib in patients with idiopathic pulmonary fibrosis. Outcomes were compared in patients at GAP stage I versus II/III at baseline in the INPULSIS® trials. At baseline, 500 patients were at GAP stage I (nintedanib 304, placebo 196), 489 were at GAP stage II (nintedanib 296, placebo 193) and 71 were at GAP stage III (nintedanib 38, placebo 33). In nintedanib-treated patients, the annual rate of decline in forced vital capacity (FVC) was similar in patients at GAP stage I and GAP stage II/III at baseline (-110.1 and -116.6 mL·year-1, respectively), and in both subgroups was lower than in placebo-treated patients (-218.5 and -227.6 mL·y
SUBMITTER: Ryerson CJ
PROVIDER: S-EPMC6487272 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA